Brief: Ascletis Announces U.S. IND Approval Of ASC22 (Envafolimab) For Immune Restoration/Functional Cure Of HIV-1 Infected Patients
11/05/2022 01:43
May 10 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS ANNOUNCES U.S. IND APPROVAL OF ASC22
(ENVAFOLIMAB) FOR
IMMUNE RESTORATION/FUNCTIONAL CURE OF HIV-1 INFECTED PATIENTS
Source text for Eikon: ID:nPn55sMCKa
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026